Benefits of proposed faster drug approval in the UK questionable

Benefits of proposed faster drug approval in the UK questionable PharmacoEconomics & Outcomes News 792, p31 - 2 Dec 2017 Benefits of proposed faster drug approval in the UK questionable The UK’s government proposed scheme of accelerated access to new drugs and technologies is unlikely to improve patient outcomes, say professors of health policy from the London School of Economics and Political Science in London, UK. In their comment published in the BMJ, the professors question the benefits of the proposed scheme, which aims to expedite development and approval of promising new technologies, and their adoption in the NHS. The professors caution that, according to research, most products with accelerated approval "do not offer a step change in patient outcomes". The proposal "says too little on expected benefits for patients and wider society," note the professors. They also suggest that another important issue is that the selection process of such promising technologies relies on early studies, which tend to exaggerate benefits. Furthermore, they caution that faster access to new drugs and technologies is more likely to escalate, rather than control healthcare spending. Innovations that save money are very rare, and it is doubtful that the extra costs can be offset by identifying and expediting other products that generate savings. The proposal of accelerated access is a "bold attempt to strike a balance between health and industrial policy," note the professors. They conclude "we should focus on better not faster approvals and send a clear message to industry about the needs and priorities of the NHS and all who use it." Naci H, et al. Accelerated access to new drugs and technologies BMJ : 22 Nov 2017. Available from: URL: https://doi.org/10.1136/bmj.j5387 803284964 1173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Dec 2017 No. 792 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png PharmacoEconomics & Outcomes News Springer Journals

Benefits of proposed faster drug approval in the UK questionable

Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/benefits-of-proposed-faster-drug-approval-in-the-uk-questionable-sSHMj1CvjW
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Public Health
ISSN
1173-5503
eISSN
1179-2043
D.O.I.
10.1007/s40274-017-4554-y
Publisher site
See Article on Publisher Site

Abstract

PharmacoEconomics & Outcomes News 792, p31 - 2 Dec 2017 Benefits of proposed faster drug approval in the UK questionable The UK’s government proposed scheme of accelerated access to new drugs and technologies is unlikely to improve patient outcomes, say professors of health policy from the London School of Economics and Political Science in London, UK. In their comment published in the BMJ, the professors question the benefits of the proposed scheme, which aims to expedite development and approval of promising new technologies, and their adoption in the NHS. The professors caution that, according to research, most products with accelerated approval "do not offer a step change in patient outcomes". The proposal "says too little on expected benefits for patients and wider society," note the professors. They also suggest that another important issue is that the selection process of such promising technologies relies on early studies, which tend to exaggerate benefits. Furthermore, they caution that faster access to new drugs and technologies is more likely to escalate, rather than control healthcare spending. Innovations that save money are very rare, and it is doubtful that the extra costs can be offset by identifying and expediting other products that generate savings. The proposal of accelerated access is a "bold attempt to strike a balance between health and industrial policy," note the professors. They conclude "we should focus on better not faster approvals and send a clear message to industry about the needs and priorities of the NHS and all who use it." Naci H, et al. Accelerated access to new drugs and technologies BMJ : 22 Nov 2017. Available from: URL: https://doi.org/10.1136/bmj.j5387 803284964 1173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Dec 2017 No. 792

Journal

PharmacoEconomics & Outcomes NewsSpringer Journals

Published: Dec 2, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off